Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.
Key Details
- 1Researchers analyzed data from 109 multiple myeloma patients undergoing stem cell mobilization.
- 2Machine learning models identified time periods with low risk for serious side effects during therapy.
- 3Models could accurately predict the timing and occurrence of certain side effects in individual patients.
- 4Enables more patients to safely undergo chemotherapy and stem cell mobilization as outpatients.
- 5Outpatient treatment improves quality of life and allows for better hospital resource management.
- 6Findings published in npj Digital Medicine by Göttingen and Bielefeld researchers.
Why It Matters
By accurately stratifying patient risk using AI, more multiple myeloma patients could receive therapy outside the hospital, reducing healthcare costs and improving patient experience. This study highlights the growing role for AI in personalizing oncology care pathways.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.